Ibopamine in the treatment of mild chronic heart failure in elderly patients: A double-blind, placebo-controlled study

Benzi Azzolini; C. Pizzomi; E. Guffanti; M. Ronzitti; L. Tantalo

doi:10.1159/000174702

Ibopamine in the treatment of mild chronic heart failure in elderly patients: A double-blind, placebo-controlled study

Benzi Azzolini, C. Pizzomi, E. Guffanti, M. Ronzitti, L. Tantalo

Istituto Nazionale di Riposo e Cura per Anziani V.E. II

Research output: Contribution to journal › Article

Abstract

This double-blind, randomized, multicentcr clinical study assessed the efficacy and safety of ibopamine 100 mg t.i.d. as monotherapy vs. placebo in 52 patients with mild chronic heart failure aged over 60 years during a 12-weektreatment period. Ibopamine produced a statistically significant increase in exercise tolerance and reduction in fatigue during effort compared to placebo. A trend towards decreased requirement of concomitant diuretic therapy was noted in the ibopaminc-treated group. Ibopamine was well tolerated throughout the study. This study indicated that ibopamine is an effective and safe agent as monotherapy in the treatment of mild chronic heart failure in elderly patients.

Original language	English
Pages (from-to)	89-95
Number of pages	7
Journal	Cardiology
Volume	77
DOIs	https://doi.org/10.1159/000174702
Publication status	Published - 1990

Fingerprint

Keywords

Chronic
Elderly
heart failure

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Pharmacology (medical)

Cite this

Azzolini, B., Pizzomi, C., Guffanti, E., Ronzitti, M., & Tantalo, L. (1990). Ibopamine in the treatment of mild chronic heart failure in elderly patients: A double-blind, placebo-controlled study. Cardiology, 77, 89-95. https://doi.org/10.1159/000174702

@article{67ad04e5d566494ebccf35c4e37c1060,

title = "Ibopamine in the treatment of mild chronic heart failure in elderly patients: A double-blind, placebo-controlled study",

abstract = "This double-blind, randomized, multicentcr clinical study assessed the efficacy and safety of ibopamine 100 mg t.i.d. as monotherapy vs. placebo in 52 patients with mild chronic heart failure aged over 60 years during a 12-weektreatment period. Ibopamine produced a statistically significant increase in exercise tolerance and reduction in fatigue during effort compared to placebo. A trend towards decreased requirement of concomitant diuretic therapy was noted in the ibopaminc-treated group. Ibopamine was well tolerated throughout the study. This study indicated that ibopamine is an effective and safe agent as monotherapy in the treatment of mild chronic heart failure in elderly patients.",

keywords = "Chronic, Elderly, heart failure",

author = "Benzi Azzolini and C. Pizzomi and E. Guffanti and M. Ronzitti and L. Tantalo",

year = "1990",

doi = "10.1159/000174702",

language = "English",

volume = "77",

pages = "89--95",

journal = "Cardiology",

issn = "0008-6312",

publisher = "S. Karger AG",

}

TY - JOUR

T1 - Ibopamine in the treatment of mild chronic heart failure in elderly patients

T2 - A double-blind, placebo-controlled study

AU - Azzolini, Benzi

AU - Pizzomi, C.

AU - Guffanti, E.

AU - Ronzitti, M.

AU - Tantalo, L.

PY - 1990

Y1 - 1990

N2 - This double-blind, randomized, multicentcr clinical study assessed the efficacy and safety of ibopamine 100 mg t.i.d. as monotherapy vs. placebo in 52 patients with mild chronic heart failure aged over 60 years during a 12-weektreatment period. Ibopamine produced a statistically significant increase in exercise tolerance and reduction in fatigue during effort compared to placebo. A trend towards decreased requirement of concomitant diuretic therapy was noted in the ibopaminc-treated group. Ibopamine was well tolerated throughout the study. This study indicated that ibopamine is an effective and safe agent as monotherapy in the treatment of mild chronic heart failure in elderly patients.

AB - This double-blind, randomized, multicentcr clinical study assessed the efficacy and safety of ibopamine 100 mg t.i.d. as monotherapy vs. placebo in 52 patients with mild chronic heart failure aged over 60 years during a 12-weektreatment period. Ibopamine produced a statistically significant increase in exercise tolerance and reduction in fatigue during effort compared to placebo. A trend towards decreased requirement of concomitant diuretic therapy was noted in the ibopaminc-treated group. Ibopamine was well tolerated throughout the study. This study indicated that ibopamine is an effective and safe agent as monotherapy in the treatment of mild chronic heart failure in elderly patients.

KW - Chronic

KW - Elderly

KW - heart failure

UR - http://www.scopus.com/inward/record.url?scp=0024990668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024990668&partnerID=8YFLogxK

U2 - 10.1159/000174702

DO - 10.1159/000174702

M3 - Article

C2 - 2279258

AN - SCOPUS:0024990668

VL - 77

SP - 89

EP - 95

JO - Cardiology

JF - Cardiology

SN - 0008-6312

ER -

Access to Document

10.1159/000174702